David Lebowitz

Stock Analyst at Citigroup

(3.96)
# 621
Out of 5,044 analysts
119
Total ratings
59.77%
Success rate
8.69%
Average return

Stocks Rated by David Lebowitz

Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69$84
Current: $72.99
Upside: +15.08%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77$84
Current: $60.18
Upside: +39.58%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56$48
Current: $27.37
Upside: +75.37%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35$20
Current: $22.17
Upside: -9.79%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243$290
Current: $203.23
Upside: +42.70%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88$103
Current: $93.08
Upside: +10.66%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31$38
Current: $35.93
Upside: +5.76%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15$22
Current: $16.20
Upside: +35.80%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58$67
Current: $63.56
Upside: +5.41%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45$56
Current: $39.99
Upside: +40.04%
Maintains: Neutral
Price Target: $14$10
Current: $14.79
Upside: -32.39%
Maintains: Neutral
Price Target: $4$1.5
Current: $1.80
Upside: -16.67%
Maintains: Sell
Price Target: $32$45
Current: $67.08
Upside: -32.92%
Maintains: Buy
Price Target: $65$68
Current: $71.65
Upside: -5.09%
Initiates: Buy
Price Target: $382
Current: $435.78
Upside: -12.34%
Maintains: Neutral
Price Target: $103$96
Current: $52.67
Upside: +82.27%
Maintains: Equal-Weight
Price Target: $18$12
Current: $6.30
Upside: +90.48%
Maintains: Equal-Weight
Price Target: $170$164
Current: $478.58
Upside: -65.73%
Maintains: Overweight
Price Target: $36$39
Current: $19.64
Upside: +98.57%
Maintains: Equal-Weight
Price Target: $20$21
Current: $13.11
Upside: +60.18%
Maintains: Overweight
Price Target: $435$405
Current: $6.42
Upside: +6,208.41%
Maintains: Equal-Weight
Price Target: $13$14
Current: $1.63
Upside: +758.90%